Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp To Discuss The Registrational PIONEER Trial Data Of AYVAKIT In Indolent SM Call Transcript

Feb 27, 2023 / 01:00PM GMT
Release Date Price: $40.52 (+6.72%)
Operator

Thank you all for joining. I would like to welcome you all to this morning's Blueprint Medicines Conference Call. My name is Brika, and I'll be your operator for today's call. (Operator Instructions)

I would now like to turn the call over to Jenna Cohen. You may begin.

Jenna Cohen
Blueprint Medicines Corporation - Senior Director & Head of IR

Thank you, Brika. Good morning, everyone, and welcome to Blueprint Medicines conference call to discuss the presentation of our detailed AYVAKIT data in patients with indolent systemic mastocytosis. Yesterday afternoon, we issued a press release, which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

Joining me on today's call are Kate Haviland, Chief Executive Officer; Dr. Becker Hewes, Chief Medical Officer; and Dr. Mariana Castells, Director of the Mastocytosis

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot